Who are Testosterone MD-Lotion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intrinsa Transdermal testosterone patch, Andriol Testocaps, Testosterone Undecanoate and/or PDE-5, Androgel (Testosterone Gel), therapeutic testosterone, Testosterone gel 1%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/testosterone-md-lotion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Testosterone MD-Lotion — Competitive Intelligence Brief

Testosterone MD-Lotion (Testosterone MD-Lotion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen replacement therapy. Area: Endocrinology.

phase 3 Androgen replacement therapy Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Testosterone MD-Lotion (Testosterone MD-Lotion) — Acrux DDS Pty Ltd. Testosterone MD-Lotion delivers testosterone through the skin to replace deficient levels in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Testosterone MD-Lotion TARGET	Testosterone MD-Lotion	Acrux DDS Pty Ltd	phase 3	Androgen replacement therapy
Intrinsa Transdermal testosterone patch	Intrinsa Transdermal testosterone patch	Imperial College Healthcare NHS Trust	marketed	Androgen replacement therapy	Androgen receptor
Andriol Testocaps	Andriol Testocaps	Singapore Clinical Research Institute	marketed	Androgen replacement therapy	Androgen receptor
Testosterone Undecanoate and/or PDE-5	Testosterone Undecanoate and/or PDE-5	Hospital Santa Fe	marketed	Androgen replacement therapy combined with PDE-5 inhibitor	Androgen receptor (testosterone undecanoate); phosphodiesterase-5 (PDE-5 inhibitor component)
Androgel (Testosterone Gel)	Androgel (Testosterone Gel)	National Institute on Aging (NIA)	marketed	Androgen replacement therapy	Androgen receptor
therapeutic testosterone	therapeutic testosterone	Memorial Sloan Kettering Cancer Center	marketed	Androgen replacement therapy	Androgen receptor (AR)
Testosterone gel 1%	Testosterone gel 1%	University of Colorado, Denver	marketed	Androgen replacement therapy	Androgen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen replacement therapy class)

Clarus Therapeutics, Inc. · 2 drugs in this class
Acerus Pharmaceuticals Corporation · 1 drug in this class
Acrux DDS Pty Ltd · 1 drug in this class
Alliance for Clinical Trials in Oncology · 1 drug in this class
Bayer · 1 drug in this class
Beersheva Mental Health Center · 1 drug in this class
Imperial College Healthcare NHS Trust · 1 drug in this class
Laboratoires Besins International · 1 drug in this class
Lipocine Inc. · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Testosterone MD-Lotion — Competitive Intelligence Brief. https://druglandscape.com/ci/testosterone-md-lotion. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab